The IRGQ Knockout TE1 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population in the TE1 human esophageal squamous cell carcinoma background, featuring targeted disruption of the IRGQ gene. This polyclonal pool enables loss-of-function studies while preserving the genetic heterogeneity inherent to a cell population without clonal selection.
The TE1 cell line is an established model of human esophageal squamous cell carcinoma, originally derived from a male patient. It is widely employed in esophageal cancer research to investigate tumor biology, drug response, and signaling mechanisms. TE1 cells maintain key characteristics of the squamous differentiation lineage and are amenable to genetic manipulation and downstream phenotypic assays.
IRGQ belongs to the interferon-inducible GTPase superfamily and is implicated in the regulation of autophagy and innate immune responses. Its expression is transcriptionally activated by interferon-?? (IFNG) via the JAK1/2-STAT1 signaling axis, and it can also be regulated by NF-??B. IRGQ interacts with autophagy-related proteins including IRGM, ATG5, and BECN1, and modulates the lipidation and puncta formation of LC3B, a hallmark of autophagosome formation, while also affecting the turnover of the autophagy cargo receptor p62/SQSTM1. These molecular interactions position IRGQ at the nexus of immune signaling and autophagic flux, potentially influencing pathogen clearance and cellular homeostasis.
In the TE1 esophageal cancer context, IRGQ may contribute to tumor cell survival under stress conditions, including those induced by chemotherapeutics or immune effectors. Disruption of IRGQ in these cells allows researchers to dissect its role in autophagy-mediated therapy resistance and immune evasion mechanisms specific to squamous cell carcinoma. The knockout model provides a platform to assess how loss of IRGQ alters sensitivity to anticancer agents and affects interferon-driven immune responses, thereby illuminating potential vulnerabilities in esophageal cancer.
This polyclonal knockout cell product supports a range of experimental applications, including investigation of autophagy-mediated therapy resistance, elucidation of immune escape pathways, and synthetic lethal screening to identify druggable partners. Researchers can employ western blotting to monitor changes in LC3B and p62/SQSTM1 levels, immunofluorescence for LC3 puncta quantification, RT-qPCR for IRGQ and interferon-stimulated gene expression, apoptosis assays, and drug sensitivity profiling. These applications facilitate mechanistic dissection and translational research. For further details or technical consultation, please contact Ascent Research.
